Anifrolumab, an Anti-Interferon Alpha Receptor Monoclonal Antibody, in Moderate to Severe Systemic Lupus Erythematosus (SLE)

被引：0

作者：

Furie, Richard ^{[1
]}

Merrill, J. T. ^{[2
]}

Werth, V. P. ^{[3
,4
]}

Khamashta, M. ^{[5
]}

Kalunian, K. ^{[6
]}

Brohawn, P. ^{[7
]}

Illei, G. ^{[7
]}

Drappa, J. ^{[7
]}

Wang, L. ^{[7
]}

Yoo, S. ^{[8
]}

机构：

[1] North Shore LIJ Hlth Syst, New York, NY USA

[2] Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA

[3] Philadelphia VA Med Ctr, Philidelphia, PA USA

[4] Univ Penn, Philadelphia, PA 19104 USA

[5] St Thomas Hosp, Rayne Inst, Graham Hughes Lupus Res Lab, London SE1 7EH, England

[6] UCSD, Sch Med, La Jolla, CA USA

[7] MedImmune, Gaithersburg, MD USA

[8] Regenx Bio, Rockville, MD USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2015年 / 67卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

3223

引用

页数：4

共 50 条

[21] Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
Rajesh Narwal
Lorin K. Roskos
Gabriel J. Robbie
[J]. Clinical Pharmacokinetics, 2013, 52 : 1017 - 1027
[22] Population Pharmacokinetics of Sifalimumab, an Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus
Narwal, Rajesh
Roskos, Lorin K.
Robbie, Gabriel J.
[J]. CLINICAL PHARMACOKINETICS, 2013, 52 (11) : 1017 - 1027
[23] A Phase 3 Randomized Controlled Trial of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus
Furie, Richard
Morand, Eric
Bruce, Ian
Manzi, Susan
Kalunian, Kenneth
Vital, Edward
Lawrence-Ford, Theresa
Gupta, Ramesh
Hiepe, Falk
Santiago, Mittermayer
Brohawn, Philip
Berglind, Anna
Tummala, Raj
[J]. ARTHRITIS & RHEUMATOLOGY, 2019, 71
[24] Monoclonal Antibodies for Systemic Lupus Erythematosus (SLE)
Ponticelli, Claudio
Moroni, Gabriella
[J]. PHARMACEUTICALS, 2010, 3 (01): : 300 - 322
[25] ALPHA-INTERFERON AND ANTIBODY TO ALPHA-INTERFERON IN SYSTEMIC LUPUS-ERYTHEMATOSUS
PANEM, S
CHECK, IJ
HENRIKSEN, D
VILCEK, J
[J]. UCLA SYMPOSIA ON MOLECULAR AND CELLULAR BIOLOGY, 1982, 25 : 233 - 240
[26] Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
Chia, Yen Lin
Tummala, Raj
Mai, Tu H.
Rouse, Tomas
Streicher, Katie
White, Wendy, I
Morand, Eric F.
Furie, Richard A.
[J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 62 (09): : 1094 - 1105
[27] Anti-Interferon Autoantibodies in Systemic Lupus Erythematosus Are Biologically Active and Have Distinct Functions
Gupta, Sarthak
Tatouli, Ioanna P.
Rosen, Lindsey B.
Hasni, Sarfaraz
Alevizos, Illias
Manna, Zerai G.
Rivera, Juan
Jiang, Chao
Siegel, Richard M.
Holland, Steven M.
Moutsopoulos, Haralampos M.
Browne, Sarah K.
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[28] Functional and Mechanistic Characterization of Anifrolumab, a Fully Human, Anti-IFNAR1 Monoclonal Antibody for the Treatment of Systemic Lupus Erythematosus
Riggs, Jeffrey
Naiman, Brian
Zhang, Jing
Xu, Yan
Vainshtein, Inna
Hay, Carl
Schifferli, Kevin
Cardarelli, Pina
Liang, Meina
Roskos, Lorin
Connor, Jane
Kolbeck, Roland
Coyle, Anthony
Fung, Michael
[J]. ARTHRITIS & RHEUMATOLOGY, 2015, 67
[29] Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
Felten, Renaud
Scher, Florence
Sagez, Flora
Chasset, Francois
Arnaud, Laurent
[J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1535 - 1543
[30] Population Pharmacokinetics of Sifalimumab, An Investigational Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus Patients
Narwal, Rajesh
Roskos, Lorin
White, Wendy
Greth, Warren
Robbie, Gabriel
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S546 - S546

← 1 2 3 4 5 →